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The role of noninvasive ventilation in cancer patients with acute respiratory failure
Shruti Nagarkar
The poor prognosis of ventilated patients with cancers, especially hematological malignancies, has been a major incentive in the use non-invasive ventilation in such patients. With experience of more than a decade, a few recommendations can be made. While experience in non invasive ventilation is of prime importance, it is the early use especially in conditions requiring supplemental oxygen and a drop in SaO of > 10% that 2 the most benefit is expected. Use of the helmet to provide noninvasive ventilation (NIV) may improve patient compliance. With appropriate use during diagnostic bronchoscopy, NIV may prevent endotracheal intuba tion. NIV has also been shown to provide relief from dyspnoea to a select group of do-not-intubate patients.
While outcome in this group of patients is poor, appropriate use of NIV has been shown to reduce mortality.
The coming years and more experience will improve our understanding and refine the use of this modality in this critical condition.
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The last decade has seen an increasing confi dence in with hematological malignancies needing mechanical the use of noninvasive ventilation in the management ventilation have mortality rates of 70-80%. Even patients of respiratory failure, especially hypercapnic respiratory with solid organ tumors requiring mechanical ventilation, failure. The low incidence of nosocomial respiratory unrelated to surgery, have a poor hospital outcome with infections with the use of this modality is its most attractive feature. a 70-90% mortality.
While this appears very disappointing, the last decade Acute respiratory failure is the commonest indication for has seen a three-fold improvement in prognosis in this admission to ICU in patients with cancer and mortality group of sick patients. [2, 3] in this group remains at least three times higher than admission from any other cause. [1] Mortality varies This has been ascribed to improvements in [2] In his retrospective analysis of matched cohorts in two time periods, only two variables showed an association with mortality: the severity of the patients' condition on admission to the ICU and the need for mechanical ventilation. noninvasively had a better outcome compared to those needing invasive ventilation. In reviewing the mortality in mechanically ventilated patients, Azoulay and Schlemmer found that invasive mechanical ventilation was associated with a 75% mortality, as compared to 50% with NIV. [4] Both, classical prognostic factors e.g. presence of neutropenia, type of malignancy and physiological scores are not helpful in triaging patients to ICU. [2, 3, 5] However, Though pilot studies done through the 90's showed a benefit, it was the publication by Hilbert et al in 2001, which gave an impetus to the modality in this clinical scenario.
In this prospective randomized trial [10] intermittent NIV was compared to standard treatment with supplemental oxygen and no ventilatory support, in fifty two immunosuppressed patients with pulmonary infiltrates, fever and an early stage of hypoxemic acute respiratory the nature and number of organ failures at admission failure (PaO 2 /FiO 2 ratio <200). The large majority of the and the rapidity with which multiorgan failure ensues is patients had a hematologic malignancy and neutropenia directly correlated with risk of death. [6, 7] or drug-induced immunosuppression. Periods of NIV delivered through a facemask were alternated every The differential diagnosis of ARF in cancer [4] three hours with periods of spontaneous breathing with includes:
supplemental oxygen. The decision to intubate was Progression or spread of underlying cancer made according to standard, predetermined criteria.
ARDS
The main results of the study were that fewer patients Infection in the NIV group than in the standard-treatment group Chemotherapy or radiation induced lung injury required endotracheal intubation (12 vs 20; P = 0.03), Pulmonary thromboembolism had serious complications (13 vs 21; P = 0.02), died in Tumour emboli the ICU (10 vs 18; P = 0.03) or died in the hospital (13 vs Diffuse alveolar hemorrhage 21; P = 0.02). Overall, this study clearly showed that early Pulmonary leukostasis implementation of NIV was associated with significant Lymphangitic carcinomatosis reduction in the rate of intubation, serious complications Transfusion related lung injury and death, both in the ICU and in the hospital. Airway obstruction Paraneoplastic syndromes Hilbert used intermittent NIV, very early in his series of hypoxemic patients. The above are associated with a primarily hypoxemic lung injury pattern. With such pathophysiology, prognosis NIV improves hypoxemic ARF by physiologic can be worse than in patients who have a hypercapnic mechanisms related to PEEP, such as recruitment of respiratory failure, which is independent of the underlying underventilated alveoli, redistribution of extravascular disease state or a cardiogenic pulmonary edema. lung water, prevention of atelectasis and high FiO induced lung toxicity, as well as to those related to the It is imperative to understand thoroughly how to put our inspiratory assist by pressure support involving the newfound confidence in this technique to best use in this reduction in the work of breathing and an increase in tidal group of patients. volume with adequate alveolar ventilation.
NIV in Cancer
That invasion of the respiratory tract by the endotracheal tube contributes to increased rates of nosocomial infections is well established.
[8] This uncompromising fact led clinicians to use NIV on immunocompromised patients as early as 1990, when case controlled studies showed that NIV was an effective supportive therapy.
Tognet et al reported the first improvement in outcome with the use in patients with hematological malignancies. [9] In immunocompromized patients with ARF caused by pneumonia and ARDS, interruption of NPPV can rapidly worsen gas exchange, sometimes leading to NPPV failure and endotracheal intubation. If NIV is attempted via a facial mask for a longer time frame, compliance may be an issue. Improved compliance and tolerability of NIV with the helmet as the interface avoids the need for NPPV discontinuation. The helmet allows the patients to freely communicate, drink and expectorate, improving collaboration with caregivers and clearance of the airways. Rocco in a case-controlled study [11] has demonstrated the use of the helmet as a valid alternative to a facemask in immunocompromized patients with lung infi ltrates and hypoxemic ARF. They were able to increase the number of hours of continuous NPPV without interruptions and decrease the rate of complications directly related to the administration of NPPV. It is necessary to remember that CO 2 washout is suboptimal with the helmet. [12] All patients with cancer and pneumonia do not radiological and oxygenation parameters, the presence of hepatic failure, Gram-negative bacilli isolated in blood culture, poor performance status, cancer status, older age and the number of organ failures at admission to ICU.
[17] The appropriate use of such easily available clinical characteristics will help in deciding about the use of NIV.
Yet another use of NIV is to avoid intubation during and after diagnostic flexible fi breoptic bronchoscopy necessarily need ventilatory support. The time after in patients with early or borderline respiratory failure onset of pneumonia and transfer to ICU can be up to undergoing diagnostic bronchoscopy and broncho seven days and delay in initiating supportive therapy can alveolar lavage. Either CPAP or pressure support worsen outcomes.
[10] Therefore, Gruson et al. attempted ventilation may be used and may be delivered either via to define variables which would predict the need of full-face mask or helmet. [18] [19] [20] transfer to ICU. In their series of fifty three patients, [13] the factors associated with ICU admission were: numbers of
The dilemma of how to provide relief to a terminally ill involved quadrants: 2.3 vs 1, (P =0.001) and oxygenation cancer patient with ARF, especially one with specifi c DNR parameters (initial level of oxygen supplementation: 3.5 or a do-not-intubate order is faced by most of us. NIV vs 0.9 l/min, P<0.05), the presence of hepatic failure (58% can provide relief of dyspnoea and sometimes reverse vs 10%, P<0.01), Gram negative bacilli isolated in blood the acute deterioration. Levy [21] has shown that despite a culture (7 vs 1, P=0.01) . In the multivariate analysis, a high overall mortality rate, when such patients are treated decrease of 10% in the SaO 2 and the requirement of nasal with NPPV, those with diagnoses such as congestive at the onset of acute respiratory failure heart failure or chronic obstructive pulmonary disease, 2 increased the risk of admission to MICU. who have a strong cough or who are awake have a better prognoses. At present, the ability to predict success with the use of NIV is best for hypercapnic respiratory failure. No indices It can be argued that this may merely prolong the are uniformly suitable for the multiple pathophysiological process of dying but such studies add to our ability to processes leading to hypoxic respiratory failure. [14] counsel families and patients with conviction. Therefore, when NIV is used in acute hypoxemic respiratory failure it is mandatory to set definite end points
Conclusion and criteria for invasive ventilation. Patients who have
While the outcome of critically ill cancer patients is still delayed intubation have a poor prognosis. [15] Azoulay disappointing, it has been demonstrated that avoidance and his colleagues found that patients who required of invasive ventilation is associated with a better outcome. only NIV had a 15% mortality, while those that had late NIV is a feasible alternative to intubation in specific failure of NIV (requiring intubation after 48h of NIV) had groups of patients. The two keys to successful use being a 93% mortality and those who had a noncardiac cause experience and training of the staff involved in care supplementary O of respiratory failure and required intubation after three days of NIV had a 100% mortality. [16] It must be noted at this point, that NIV in hypoxemic respiratory failure, even in a non cancer setting, is not an alternative ventilatory mode and is useful only in the very early or initial setting of the pathology.
Certain factors are predictive of the need for invasive mechanical ventilation and a poor outcome. They are and the timing i.e., the early use of the technique. We encounter many challenges in the successful treatment of this group of patients and the coming years with well-designed trials may improve our ability to improve outcomes. ) .
